TKIs, including gefitinib and erlotinib, have become the standard first-line therapy for patients with advanced NSCLC that harbor activating EGFR mutations11, 12, especially for women and patients who have never smoked. This evidence concerns the gene EGFR and non-small cell lung carcinoma.